American Diabetes Association, CVS Health Announce Expansion of Free Lifestyle-Change Program to Help Address Racial Disparities in Diabetes Diagnosis for Adults with Type 2 Diabetes – Yahoo Finance

American Diabetes Association’s Project Power is helping turn a type 2 diagnosis into healthy action
ARLINGTON, Va., Dec. 5, 2022 /PRNewswire/ — The American Diabetes Association^® (ADA) and partner CVS Health today announced the expansion of Project Power, an innovative diabetes lifestyle change program that will raise diabetes awareness, help combat disparities in diagnosis among communities of color, and offer diabetes risk reduction education to people with type 2 diabetes and prediabetes nationwide. Project Power is a no-cost program that uses an outcomes-based curriculum. With support from strategic partner CVS Health, the ADA is now rolling out programming for adults in order to deliver the same impact within families.
“The goal of Project Power is to help increase health equity, eliminate disparities in the diagnosis and treatment of diabetes, and build a future without type 2 diabetes,” said Chuck Henderson, ADA’s Chief Executive Officer. “ADA’s health equity focus means empowering people of color who live with type 2 diabetes and prediabetes to manage their health and live better, fuller lives.”
Type 2 diabetes can be prevented or delayed, however, according to the 2022 National Diabetes Statistics Report-CDC, over 37 million Americans have diabetes, and another 96 million are living with prediabetes, a condition that puts you at risk for type 2 diabetes. Prevalence of diagnosed diabetes was highest among American Indians and Alaska Natives (14.5%), followed by non-Hispanic Blacks (12.1%), people of Hispanic origin (11.8%), non-Hispanic Asians (9.5%) and non-Hispanic Whites (7.4%) (source). Project Power is a diabetes risk reduction program that will educate the public on diabetes and remove barriers to treatment—including destigmatizing diabetes and identifying and removing social determinants of health-related barriers.
In September 2022, Project Power’s impact was felt by people in communities of color in Texas. The Project Power team implemented the program at Garland Independent School District (GISD), the second-largest district in Dallas County. This is a diverse community with demographics that include 54% Hispanic/Latinx, 19% Black/African American, and 9% Asian population—with 67% of students experiencing economic disadvantages. Through ADA’s Project Power, approximately 80 coaches were trained in their P.E. class in August before the program started in September. Over 22,000 students from 49 elementary schools are currently being impacted by participating in Project Power for youth.
To sign-up for the ADA’s free Project Power program, visit diabetes.org/ProjectPower.
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 82 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 133 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn). 
Contact:  Rebecca Fisher, 703-253-4918
press@diabetes.org
 
View original content to download multimedia:https://www.prnewswire.com/news-releases/american-diabetes-association-cvs-health-announce-expansion-of-free-lifestyle-change-program-to-help-address-racial-disparities-in-diabetes-diagnosis-for-adults-with-type-2-diabetes-301695034.html
SOURCE American Diabetes Association
CVS provides service to millions of people around the U.S. for their healthcare needs, but with so many customers to serve, the drugstore chain does find itself mired in controversy every so often. From complaints about the company's hand sanitizer to claims about misleading medications, CVS has been hit with a number of consumer lawsuits this year. And while most of these suits are resolved with little fanfare, one lawsuit is now drawing enough negative attention that some shoppers are calling
BTIG upgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate's benefit, Gossamer Bio Inc's (NASDAQ: GOSS) TORREY Phase 2 results validated dry powder inhaled (DPI)-administered TKIs in pulmonary arterial hypertension (PAH) as a safe and technically viable approach. But Gossamer's DPI seralutinib does not look like a competitive disease-modifying therapy in PAH, with a PVR reduction of only 14% in the overall study popu
The company focuses on therapies to treat chronic debilitating conditions and after the market closed on Monday, it released phase 2 trial results for its lead therapy, NE3107, to treat Alzheimer's disease and Parkinson's disease. The therapy was more effective (6 points) higher when used on Parkinson's patients who were under 70. BioVie also tested NE3107 as a monotherapy in mild Alzheimer's patients and said patients showed 2.1 points of improvement in enhanced cognition on the modified Alzheimer's Disease Assessment Scale (ADAS).
Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.
The data presented for Eisai and Biogen’s drug wasn’t convincing enough to settle a debate among experts, but investors are betting on commercial success anyway.
Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity.
Her friend and co-star John Travolta called her one of the "most special relationships I’ve ever had."
Consider, for instance, Editas Medicine (NASDAQ: EDIT) and BioXcel Therapeutics (NASDAQ: BTAI). Let's consider why Editas Medicine and BioXcel Therapeutics are worth keeping an eye on right now, and whether the potential rewards of investing in these companies outweigh the risks. The company is down by 61% this year, a terrible performance it partly owes to market-wide troubles.
Kirstie Alley was diagnosed with colon cancer before she died. Her family says the cancer was only recently discovered. Doctors share symptoms and risk factors.
Emergent BioSolutions Inc. (NYSE: EBS) has cleared an important hurdle in a bid to make its opioid overdose antidote available to the public without a doctor’s order. The Gaithersburg company said Tuesday that the Food and Drug Administration has accepted its supplemental new drug application for Narcan Nasal Spray, currently available with a prescription, as an emergency over-the-counter treatment for opioid overdose. The FDA expects to issue its decision of approval or denial March 29, 2023.
Investing in small-cap stocks can be very risky. Let's consider two small-cap stocks that carry above-average risk but that could soar as early as next year if things work out: Bluebird Bio (NASDAQ: BLUE) and Krystal Biotech (NASDAQ: KRYS). Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses.
Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.
A Texas woman is out on bond after authorities say she repeatedly stabbed her boyfriend on Thanksgiving after accusing him of “not helping her with the bills,” according to court records. Cassandra Gutierrez, 30, was released on bond Thursday after being charged with aggravated assault with a deadly weapon for the alleged stabbing, which left her boyfriend injured but alive, Law & Crime reports. Gutierrez and her 42-year-old boyfriend had been dating for about a year when investigators said they
In this article, we will discuss the Top 10 Hearing Aid Companies and Brands in the World. You can skip our detailed industry analysis and go directly to the Top 5 Hearing Aid Companies and Brands in the World. The Hearing Aid Industry: An Analysis The traditional hearing aid devices were designed to amplify the original […]
Cannabis investors today are reacting to a historic development in the industry on Friday. Tilray shares soared nearly 12%, while Aurora and SNDL stocks were up between about 6% and 7% in early trading.
Editas Medicine Inc (NASDAQ: EDIT) announced initial clinical data from the first two sickle cell disease (SCD) patients treated with EDIT-301 in the Phase 1/2 RUBY trial. EDIT-301 is under development for the treatment of severe sickle cell disease. The clinical data includes safety data from the first two patients and efficacy data from the first patient treated. Both treated patients demonstrated successful neutrophil and platelet engraftment. Additionally, neither patient has experienced any
SEATTLE — Before dawn on a recent day in the port of Seattle, dense autumn fog hugged Puget Sound and ship-to-shore container cranes hovered over the docks like industrial sentinels. Under the dim glimmer of orange floodlights, the crew of the tugboat Millennium Falcon fired up the engines for a long day of towing oil barges and refueling a variety of large vessels, like container ships. The first thing to know about barges is that they don’t move themselves. They are propelled and guided by tug
Shares of Editas Medicine Inc. rallied 9.3% in premarket trading on Tuesday after the company said in a news release that it had positive results from the first two patients enrolled in a Phase 1/2 clinical trial assessing its experimental treatment for sickle-cell disease. Editas said the therapy was well-tolerated. "These promising clinical results from the RUBY trial suggest clinical proof of concept for EDIT-301 and support our belief that EDIT-301 can be a clinically differentiated, one-tim
The three fast-food burger giants all have the same idea (here's how you can get a free meal and some great deals).
The beloved husband and grandfather was visiting from Missouri with his wife, officials said.

source